Skip to search formSkip to main contentSkip to account menu

volitinib

Known as: SAVOLITINIB 
An orally bioavailable inhibitor of the c-Met receptor tyrosine kinase with potential antineoplastic activity. Volitinib selectively binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Narrower (2)

AZD6094HMPL-504
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Mechanisms of Acquired Resistance to Savolitinib, a Selective MET Inhibitor in MET-Amplified Gastric Cancer
PURPOSE Some gastric cancers harbor MET gene amplifications that can be targeted by selective MET inhibitors to achieve tumor… 
Highly Cited
2019
Highly Cited
2019
Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.
The VIKTORY (targeted agent eValuation In gastric cancer basket KORea) trial was designed to classify metastatic GC patients… 
2019
2019
Structural and Molecular Insight into Resistance Mechanisms of First Generation cMET Inhibitors
Many small molecule inhibitors of the cMET receptor tyrosine kinase have been evaluated in clinical trials for the treatment of… 
2019
2019
Preclinical pharmacokinetics, disposition, and translational pharmacokinetic/pharmacodynamic modeling of savolitinib, a novel selective cMet inhibitor.
Review
2019
Review
2019
Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring MET exon 14 skipping mutation: a case report
Background Pulmonary sarcomatoid carcinoma (PSC) is a rare and poorly differentiated type of non-small cell lung cancer (NSCLC… 
Review
2018
Review
2018
The Role of Circulating Tumor DNA in Renal Cell Carcinoma
Opinion statementNext-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a novel technology that can complement… 
2018
2018
Process Design and Optimization in the Pharmaceutical Industry: A Suzuki-Miyaura Procedure for the Synthesis of Savolitinib.
A multidisciplinary approach covering synthetic, physical, and analytical chemistry, high-throughput experimentation and… 
2018
2018
Characterization and validation of potential therapeutic targets based on the molecular signature of patient-derived xenografts in gastric cancer
BackgroundPatient-derived xenograft (PDX) models with definite molecular signature are attractive preclinical models for… 
2017
2017
OA 09.06 A Phase Ib Trial of Savolitinib plus Gefitinib for Chinese Patients with EGFR-Mutant MET-Amplified Advanced NSCLC
Highly Cited
2015
Highly Cited
2015
Volitinib, a potent and highly selective c‐Met inhibitor, effectively blocks c‐Met signaling and growth in c‐MET amplified gastric cancer patient‐derived tumor xenograft models
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)